ASCT (Alanine Serine Cysteine Transporters) 属于 SLC1 家族,是负责中性氨基酸转运的膜蛋白,包括 ASCT1 (SLC1A4) 和 ASCT2 (SLC1A5)。ASCTs 介导 Na+-依赖的氨基酸交换,但不利用 Na+ 梯度作为驱动力,而是通过细胞内外氨基酸的交换维持稳态。ASCT1 和 ASCT2 具有不同的底物选择性,其中 ASCT1 对丙氨酸 (alanine) 和丝氨酸 (serine) 亲和力更高,而 ASCT2 还能够运输谷氨酰胺 (glutamine),在肿瘤代谢中发挥重要作用。 ASCT2 在多种肿瘤组织中高表达,通过转运谷氨酰胺为快速生长的癌细胞提供氮源和能量,因此成为潜在的抗癌靶点。相较之下,ASCT1 主要与神经系统疾病相关,SLC1A4 基因突变可导致智力低下、产后小头畸形、痉挛和胼胝体变薄。ASCTs 为癌症和神经疾病研究提供了新策略[1]。
ASCT (Alanine Serine Cysteine Transporters) belongs to the SLC1 family and functions as a membrane protein responsible for the transport of neutral amino acids, including ASCT1 (SLC1A4) and ASCT2 (SLC1A5). ASCTs mediate Na+-dependent amino acid exchange but do not utilize the Na+ gradient as a driving force; instead, they maintain homeostasis by exchanging amino acids between the intracellular and extracellular environments. ASCT1 and ASCT2 exhibit different substrate selectivities, with ASCT1 showing a higher affinity for alanine and serine, whereas ASCT2 can also transport glutamine, playing a crucial role in tumor metabolism. ASCT2 is highly expressed in various tumor tissues, where it facilitates glutamine uptake, supplying nitrogen and energy to rapidly proliferating cancer cells, making it a potential target for cancer therapy. In contrast, ASCT1 is primarily associated with neurological disorders, as mutations in the SLC1A4 gene can lead to intellectual disability, postnatal microcephaly, spasticity, and thinning of the corpus callosum. ASCTs provide new strategies for research in both cancer and neurological diseases[1].
(R)-KMH-233 是 KMH-233 (MS-R61312) 的异构体,可作为实验中的对照化合物,而 KMH-233 是一种有效、可逆且选择性的 L 型氨基酸转运蛋白 1 (LAT1) 抑制剂,可抑制 LAT1 底物 L-亮氨酸的摄取 (IC50=18 μM) 以及细胞生长,并且即使在低浓度 (25 μM) 下仍可显著增强 Bestatin 和顺铂的疗效。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号